Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

PD-1 blockade at the time of tumor escape potentiates the immune-mediated antitumor effects of a melanoma-targeting monoclonal antibody.

They L, Michaud HA, Becquart O, Lafont V, Guillot B, Boissière-Michot F, Jarlier M, Mollevi C, Eliaou JF, Bonnefoy N, Gros L.

Oncoimmunology. 2017 Jul 20;6(10):e1353857. doi: 10.1080/2162402X.2017.1353857. eCollection 2017.

PMID:
29123966
2.

A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.

Huang A, Peng D, Guo H, Ben Y, Zuo X, Wu F, Yang X, Teng F, Li Z, Qian X, Qin FX.

Sci Rep. 2017 Feb 16;7:42687. doi: 10.1038/srep42687.

3.

Translating Treg Therapy in Humanized Mice.

Hahn SA, Bellinghausen I, Trinschek B, Becker C.

Front Immunol. 2015 Dec 14;6:623. doi: 10.3389/fimmu.2015.00623. eCollection 2015. Review.

4.

Humanized Mouse Models for Transplant Immunology.

Kenney LL, Shultz LD, Greiner DL, Brehm MA.

Am J Transplant. 2016 Feb;16(2):389-97. doi: 10.1111/ajt.13520. Epub 2015 Nov 20. Review.

5.

Use of Humanized Mice to Study the Pathogenesis of Autoimmune and Inflammatory Diseases.

Koboziev I, Jones-Hall Y, Valentine JF, Webb CR, Furr KL, Grisham MB.

Inflamm Bowel Dis. 2015 Jul;21(7):1652-73. doi: 10.1097/MIB.0000000000000446. Review.

6.

Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma.

Yoo EM, Trinh KR, Tran D, Vasuthasawat A, Zhang J, Hoang B, Lichtenstein A, Morrison SL.

J Interferon Cytokine Res. 2015 Apr;35(4):281-91. doi: 10.1089/jir.2014.0125. Epub 2014 Oct 29.

7.

A novel model of human skin pressure ulcers in mice.

Maldonado AA, Cristóbal L, Martín-López J, Mallén M, García-Honduvilla N, Buján J.

PLoS One. 2014 Oct 13;9(10):e109003. doi: 10.1371/journal.pone.0109003. eCollection 2014.

8.

Isolation of progenitors that exhibit myogenic/osteogenic bipotency in vitro by fluorescence-activated cell sorting from human fetal muscle.

Castiglioni A, Hettmer S, Lynes MD, Rao TN, Tchessalova D, Sinha I, Lee BT, Tseng YH, Wagers AJ.

Stem Cell Reports. 2014 Jan 14;2(1):92-106. doi: 10.1016/j.stemcr.2013.12.006. eCollection 2014 Jan 14. Erratum in: Stem Cell Reports. 2014;2(4):560.

9.

Generation of improved humanized mouse models for human infectious diseases.

Brehm MA, Wiles MV, Greiner DL, Shultz LD.

J Immunol Methods. 2014 Aug;410:3-17. doi: 10.1016/j.jim.2014.02.011. Epub 2014 Mar 4. Review.

10.

Human immune system development and survival of non-obese diabetic (NOD)-scid IL2rγ(null) (NSG) mice engrafted with human thymus and autologous haematopoietic stem cells.

Covassin L, Jangalwe S, Jouvet N, Laning J, Burzenski L, Shultz LD, Brehm MA.

Clin Exp Immunol. 2013 Dec;174(3):372-88. doi: 10.1111/cei.12180.

11.

Humanized mice for immune system investigation: progress, promise and challenges.

Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL.

Nat Rev Immunol. 2012 Nov;12(11):786-98. doi: 10.1038/nri3311. Epub 2012 Oct 12. Review.

12.

Human allograft rejection in humanized mice: a historical perspective.

Brehm MA, Shultz LD.

Cell Mol Immunol. 2012 May;9(3):225-31. doi: 10.1038/cmi.2011.64. Epub 2012 Feb 13. Review.

13.

Engraftment of human HSCs in nonirradiated newborn NOD-scid IL2rγ null mice is enhanced by transgenic expression of membrane-bound human SCF.

Brehm MA, Racki WJ, Leif J, Burzenski L, Hosur V, Wetmore A, Gott B, Herlihy M, Ignotz R, Dunn R, Shultz LD, Greiner DL.

Blood. 2012 Mar 22;119(12):2778-88. doi: 10.1182/blood-2011-05-353243. Epub 2012 Jan 12.

14.

Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2rγ(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease.

Covassin L, Laning J, Abdi R, Langevin DL, Phillips NE, Shultz LD, Brehm MA.

Clin Exp Immunol. 2011 Nov;166(2):269-80. doi: 10.1111/j.1365-2249.2011.04462.x.

15.

Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells.

Sagoo P, Ali N, Garg G, Nestle FO, Lechler RI, Lombardi G.

Sci Transl Med. 2011 May 18;3(83):83ra42. doi: 10.1126/scitranslmed.3002076.

16.

Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model.

Issa F, Hester J, Goto R, Nadig SN, Goodacre TE, Wood K.

Transplantation. 2010 Dec 27;90(12):1321-7. doi: 10.1097/TP.0b013e3181ff8772.

17.

Humanized mouse models to study human diseases.

Brehm MA, Shultz LD, Greiner DL.

Curr Opin Endocrinol Diabetes Obes. 2010 Apr;17(2):120-5. doi: 10.1097/MED.0b013e328337282f.

Supplemental Content

Support Center